112 related articles for article (PubMed ID: 32946625)
21. Real-world utilization, patient characteristics, and treatment patterns among men with localized prostate cancer tested with the 17-gene genomic prostate score® (GPS
Nguyen AM; Carter GC; Wilson LM; Canfield S
Prostate; 2024 Jul; 84(10):922-931. PubMed ID: 38666513
[TBL] [Abstract][Full Text] [Related]
22. Unification of favourable intermediate-, unfavourable intermediate-, and very high-risk stratification criteria for prostate cancer.
Zumsteg ZS; Zelefsky MJ; Woo KM; Spratt DE; Kollmeier MA; McBride S; Pei X; Sandler HM; Zhang Z
BJU Int; 2017 Nov; 120(5B):E87-E95. PubMed ID: 28464446
[TBL] [Abstract][Full Text] [Related]
23. Prognostic utility of biopsy-derived cell cycle progression score in patients with National Comprehensive Cancer Network low-risk prostate cancer undergoing radical prostatectomy: implications for treatment guidance.
Tosoian JJ; Chappidi MR; Bishoff JT; Freedland SJ; Reid J; Brawer M; Stone S; Schlomm T; Ross AE
BJU Int; 2017 Dec; 120(6):808-814. PubMed ID: 28481440
[TBL] [Abstract][Full Text] [Related]
24. Immunohistochemical expression of Ets-related gene-transcriptional factor in adenocarcinoma prostate and its correlation with Gleason score.
Mannan R; Bhasin TS; Manjari M; Singh G; Bhatia PK; Sharma S
Indian J Pathol Microbiol; 2016; 59(4):489-495. PubMed ID: 27721279
[TBL] [Abstract][Full Text] [Related]
25. Genomic Prostate Score, PI-RADS™ version 2 and Progression in Men with Prostate Cancer on Active Surveillance.
Kornberg Z; Cowan JE; Westphalen AC; Cooperberg MR; Chan JM; Zhao S; Shinohara K; Carroll PR
J Urol; 2019 Feb; 201(2):300-307. PubMed ID: 30179620
[TBL] [Abstract][Full Text] [Related]
26. A 17-gene Panel for Prediction of Adverse Prostate Cancer Pathologic Features: Prospective Clinical Validation and Utility.
Eggener S; Karsh LI; Richardson T; Shindel AW; Lu R; Rosenberg S; Goldfischer E; Korman H; Bennett J; Newmark J; Denes BS
Urology; 2019 Apr; 126():76-82. PubMed ID: 30611659
[TBL] [Abstract][Full Text] [Related]
27. Comparison of Pathological and Oncologic Outcomes of Favorable Risk Gleason Score 3 + 4 and Low Risk Gleason Score 6 Prostate Cancer: Considerations for Active Surveillance.
Gearman DJ; Morlacco A; Cheville JC; Rangel LJ; Karnes RJ
J Urol; 2018 May; 199(5):1188-1195. PubMed ID: 29225057
[TBL] [Abstract][Full Text] [Related]
28. Is transperineal prostate biopsy more accurate than transrectal biopsy in determining final Gleason score and clinical risk category? A comparative analysis.
Scott S; Samaratunga H; Chabert C; Breckenridge M; Gianduzzo T
BJU Int; 2015 Oct; 116 Suppl 3():26-30. PubMed ID: 26260531
[TBL] [Abstract][Full Text] [Related]
29. Validation of the Decipher Test for predicting adverse pathology in candidates for prostate cancer active surveillance.
Kim HL; Li P; Huang HC; Deheshi S; Marti T; Knudsen B; Abou-Ouf H; Alam R; Lotan TL; Lam LLC; du Plessis M; Davicioni E; Fleshner N; Lane BR; Ross AE; Davis JW; Mohler JL; Trock BJ; Klein EA; Tosoian JJ; Hyndman ME; Bismar TA
Prostate Cancer Prostatic Dis; 2019 Sep; 22(3):399-405. PubMed ID: 30542054
[TBL] [Abstract][Full Text] [Related]
30. Genomic Scores are Independent of Disease Volume in Men with Favorable Risk Prostate Cancer: Implications for Choosing Men for Active Surveillance.
Nyame YA; Grimberg DC; Greene DJ; Gupta K; Kartha GK; Berglund R; Gong M; Stephenson AJ; Magi-Galluzzi C; Klein EA
J Urol; 2018 Feb; 199(2):438-444. PubMed ID: 28941920
[TBL] [Abstract][Full Text] [Related]
31. Effects of Initial Gleason Grade on Outcomes during Active Surveillance for Prostate Cancer.
Masic S; Cowan JE; Washington SL; Nguyen HG; Shinohara K; Cooperberg MR; Carroll PR
Eur Urol Oncol; 2018 Oct; 1(5):386-394. PubMed ID: 31158077
[TBL] [Abstract][Full Text] [Related]
32. PTEN Loss in Gleason Score 3 + 4 = 7 Prostate Biopsies is Associated with Nonorgan Confined Disease at Radical Prostatectomy.
Guedes LB; Tosoian JJ; Hicks J; Ross AE; Lotan TL
J Urol; 2017 Apr; 197(4):1054-1059. PubMed ID: 27693448
[TBL] [Abstract][Full Text] [Related]
33. Prostate cancer Ki-67 (MIB-1) expression, perineural invasion, and gleason score as biopsy-based predictors of prostate cancer mortality: the Mayo model.
Tollefson MK; Karnes RJ; Kwon ED; Lohse CM; Rangel LJ; Mynderse LA; Cheville JC; Sebo TJ
Mayo Clin Proc; 2014 Mar; 89(3):308-18. PubMed ID: 24486077
[TBL] [Abstract][Full Text] [Related]
34. Reliability of Gleason grading system in comparing prostate biopsies with total prostatectomy specimens.
Babaian RJ; Grunow WA
Urology; 1985 Jun; 25(6):564-7. PubMed ID: 4012946
[TBL] [Abstract][Full Text] [Related]
35. Clinical significance of prospectively assigned Gleason tertiary pattern 4 in contemporary Gleason score 3+3=6 prostate cancer.
Doshi C; Vacchio M; Attwood K; Murekeyisoni C; Mehedint DC; Badkhshan S; Azabdaftari G; Sule N; Guru KA; Mohler JL; Kauffman EC
Prostate; 2016 Jun; 76(8):715-21. PubMed ID: 26880312
[TBL] [Abstract][Full Text] [Related]
36. Outcome of Gleason 3 + 5 = 8 Prostate Cancer Diagnosed on Needle Biopsy: Prognostic Comparison with Gleason 4 + 4 = 8.
Harding-Jackson N; Kryvenko ON; Whittington EE; Eastwood DC; Tjionas GA; Jorda M; Iczkowski KA
J Urol; 2016 Oct; 196(4):1076-81. PubMed ID: 27265220
[TBL] [Abstract][Full Text] [Related]
37. Association between a 17-gene genomic prostate score and multi-parametric prostate MRI in men with low and intermediate risk prostate cancer (PCa).
Leapman MS; Westphalen AC; Ameli N; Lawrence HJ; Febbo PG; Cooperberg MR; Carroll PR
PLoS One; 2017; 12(10):e0185535. PubMed ID: 29016610
[TBL] [Abstract][Full Text] [Related]
38. Persistent Discordance in Grade, Stage, and NCCN Risk Stratification in Men Undergoing Targeted Biopsy and Radical Prostatectomy.
Alshak MN; Patel N; Gross MD; Margolis D; Hu JC
Urology; 2020 Jan; 135():117-123. PubMed ID: 31568795
[TBL] [Abstract][Full Text] [Related]
39. Gleason histologic grading of prostatic carcinoma. Correlations between biopsy and prostatectomy specimens.
Mills SE; Fowler JE
Cancer; 1986 Jan; 57(2):346-9. PubMed ID: 3942967
[TBL] [Abstract][Full Text] [Related]
40. Gleason scores from prostate biopsies obtained with 18-gauge biopsy needles poorly predict Gleason scores of radical prostatectomy specimens.
Djavan B; Kadesky K; Klopukh B; Marberger M; Roehrborn CG
Eur Urol; 1998; 33(3):261-70. PubMed ID: 9555550
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
